GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » EV-to-FCF

Rize Oncology (XCNQ:RIZE) EV-to-FCF : -1.77 (As of Apr. 10, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rize Oncology's Enterprise Value is C$0.95 Mil. Rize Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.54 Mil. Therefore, Rize Oncology's EV-to-FCF for today is -1.77.

The historical rank and industry rank for Rize Oncology's EV-to-FCF or its related term are showing as below:

XCNQ:RIZE' s EV-to-FCF Range Over the Past 10 Years
Min: -1.78   Med: 0   Max: 0
Current: -1.78

XCNQ:RIZE's EV-to-FCF is ranked worse than
100% of 465 companies
in the Biotechnology industry
Industry Median: 2.24 vs XCNQ:RIZE: -1.78

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-10), Rize Oncology's stock price is C$0.06. Rize Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.014. Therefore, Rize Oncology's PE Ratio (TTM) for today is At Loss.


Rize Oncology EV-to-FCF Historical Data

The historical data trend for Rize Oncology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology EV-to-FCF Chart

Rize Oncology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -1.50 0.45

Rize Oncology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.45 0.90 -1.08 1.36

Competitive Comparison of Rize Oncology's EV-to-FCF

For the Biotechnology subindustry, Rize Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rize Oncology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rize Oncology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Rize Oncology's EV-to-FCF falls into.


;
;

Rize Oncology EV-to-FCF Calculation

Rize Oncology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.949/-0.535
=-1.77

Rize Oncology's current Enterprise Value is C$0.95 Mil.
Rize Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rize Oncology  (XCNQ:RIZE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Rize Oncology's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.06/-0.014
=At Loss

Rize Oncology's share price for today is C$0.06.
Rize Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.014.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Rize Oncology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Rize Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Rize Oncology Business Description

Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1
Rize Oncology Inc is is a pharmaceutical company. The company is engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecule targeting soft tissue sarcoma and other cancers.
Executives
William James Garner 10% Security Holder, Director

Rize Oncology Headlines

No Headlines